Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age.

Autor: Gatts JE; Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA., Rush MC; Department of Pharmacy, Wake Forest Baptist Health, Winston-Salem, North Carolina, USA., Check JF; Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA., Samelak DM; Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA., McLean TW; Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Jazyk: angličtina
Zdroj: Pediatric dermatology [Pediatr Dermatol] 2022 May; Vol. 39 (3), pp. 389-393. Date of Electronic Publication: 2022 Mar 03.
DOI: 10.1111/pde.14966
Abstrakt: Background/objectives: Propranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants <5 weeks corrected age has not been established. The objective of this study was to assess the safety and efficacy of propranolol for treatment of IH in infants <5 weeks corrected age, or 45 weeks corrected gestational age (CGA).
Methods: We performed a single institution, retrospective review of patients treated with propranolol prior to the age of 6 months between 2017 and 2021. Patient characteristics, location of hemangioma(s), weight at initiation of treatment, dosing information, side effects, response, and duration of treatment were documented.
Results: Of 200 patients with IH treated with propranolol, 24 started treatment prior to 45 weeks CGA. Mean CGA at initiation of treatment was 42 weeks. Sixty-seven percent were female and 75% were white, non-Hispanic. Mean duration of treatment was 255 days. Twenty-two patients (92%) had clear benefit from treatment at a dose of 1-3 mg/kg/day. The most common side effects were sleep disturbance (21%), irritability (17%), and cool hands/feet (13%). There were no serious adverse events.
Conclusions: In this cohort of 24 patients with corrected age <5 weeks (CGA <45 weeks), propranolol was safe and effective for the treatment of infantile hemangiomas. Larger, prospective studies are indicated to investigate propranolol in this age group.
(© 2022 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: